Showing 2161-2170 of 3047 results for "".
- Hydrafacial and Glytone Team Up to Launch New Boosterhttps://practicaldermatology.com/news/hydrafacial-and-glytone-team-up-to-launch-new-booster/2461414/The Beauty Health Company’s Hydrafacial is rolling out a new exfoliating booster co-created with Glytone. The Glytone AHA Resurfacing Cellular Booster leverages a unique combination of three alpha hydroxy acids (AHAs) that may help improve the appearance of skin surface and textur
- EWG: FDA Must Ban Oxybenzone in Sunscreen Now!https://practicaldermatology.com/news/ewg-fda-must-ban-oxybenzone-in-sunscreen-now/2461405/The U.S. Food and Drug Administration (FDA) should ban oxybenzone in sunscreens, according to researchers at the Environmental Working Group (EWG). For decades, sunscreen makers have used oxybenzone in their products, despite concerns about its health harms. In 2021, the FDA t
- Hair Straightening Chemicals Associated with Higher Uterine Cancer Riskhttps://practicaldermatology.com/news/hair-straightening-chemicals-associated-with-higher-uterine-cancer-risk/2461397/Chemical hair straighteners may be contributing to a rise in aggressive uterine cancers a new study in the Journal of the National Cancer Institute suggests. The
- Extreme Weather and Skin Disease: What’s the Connection?https://practicaldermatology.com/news/extreme-weather-and-skin-disease-whats-the-connection/2461395/As floods, wildfires, and extreme heat events increase in frequency and severity, they pose a significant threat to global dermatological health, as many skin diseases are climate sensitive, according to The Journal of Climate Change and Health. “We wanted to provide dermatol
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s
- U.S FDA Clears EndyMed’s Hair Removal Devicehttps://practicaldermatology.com/news/fda-clears-endymeds-hair-removal-device/2461393/The US Food and Drug Administration has cleared Endymed Ltd’s Pure Laser hair removal device for the marketing and sales. The Pure Laser was developed in the Company's labs by its subsidiary Endymed Medical Ltd. The Company intends to commence marketing in the US th
- Study: Psoriasis Does Not Appear to Increase Heart Attack Risk in People with Significant Kidney Diseasehttps://practicaldermatology.com/news/study-psoriasis-does-not-appear-to-increase-heart-attack-risk-in-people-with-significant-kidney-disease/2461387/Studies have suggested that psoriasis is an independent risk factor for heart attack in the general population, but investigators recently found that in people who also have end-stage renal disease, which shares many risk factors with heart disease, it is not. “There are a lot of
- Castle Bioscience’s DecisionDx-SCC Test Boosts Mohs Surgeons' Confidencehttps://practicaldermatology.com/news/castle-biosciences-decisiondx-scc-test-boosts-mohs-surgeons-confidence/2461382/Castle Bioscience’s DecisionDx-SCC test results can assist Mohs surgeons in making risk-aligned management plans and increase confidence in their treatment decisions, according to data presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. DecisionD
- Hugel Resubmits Botulax BLA to FDAhttps://practicaldermatology.com/news/hugel-resubmits-botulax-bla-to-fda-1/2461380/Hugel resubmitted the BLA for its botulinum toxin called Botulax for smoothing glabellar lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) to advance into the U.S. market i
- ASDSA Names 2022 Patient Safety Hero Awardeeshttps://practicaldermatology.com/news/asdsa-names-2022-patient-safety-hero-awardees/2461379/Mathew Avram, MD, JD and Joel Cohen, MD received the